Compare Stocks

Date Range: 

 PfizerNovartisEli Lilly andAbbVieAbbott Laboratories
SymbolNYSE:PFENYSE:NVSNYSE:LLYNYSE:ABBVNYSE:ABT
Price Information
Current Price$45.19$91.85$264.28$115.67$121.52
50-Day Moving Average$40.07$91.60$227.61$115.19$115.27
52-Week Low$33.36$77.04$129.21$79.11$98.67
52-Week High$45.86$98.52$259.37$119.15$128.54
MarketRank™
Overall Score2.72.02.73.02.9
Analysis Score2.12.12.52.42.4
Community Score4.84.34.84.94.8
Dividend Score3.32.52.55.04.2
Ownership Score2.50.02.51.72.5
Earnings & Valuation Score0.61.31.31.30.6
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyBuy
Consensus Price Target$43.08$108.50$238.21$121.24$124.67
% Upside from Price Target-4.66% downside18.13% upside-9.86% downside4.81% upside2.59% upside
Trade Information
Market Cap$252.96 billion$210.22 billion$253.45 billion$204.30 billion$215.92 billion
Beta0.740.550.260.820.66
Average Volume26,597,1801,666,0742,412,7215,921,7814,679,732
Sales & Book Value
Annual Revenue$41.91 billion$48.66 billion$24.54 billion$45.80 billion$34.61 billion
Price / Sales6.044.3210.334.466.24
Cashflow$3.20 per share$8.39 per share$9.59 per share$13.77 per share$5.60 per share
Price / Cash14.1410.9527.568.4021.69
Book Value$11.42 per share$23.65 per share$6.09 per share$7.42 per share$18.62 per share
Price / Book3.963.8843.4015.596.53
Profitability
Net Income$9.62 billion$8.07 billion$6.19 billion$4.62 billion$4.50 billion
EPS$2.22$5.75$7.93$10.56$3.65
Trailing P/E Ratio19.3923.2539.5031.1834.23
Forward P/E Ratio13.4913.7331.398.2326.08
P/E Growth1.402.241.971.732.30
Net Margins23.06%17.83%23.91%12.40%15.85%
Return on Equity (ROE)26.93%25.25%132.28%150.27%27.00%
Return on Assets (ROA)10.83%10.74%16.36%14.04%12.39%
Dividend
Annual Payout$1.56$2.08$3.40$5.20$1.80
Dividend Yield3.45%2.26%1.29%4.50%1.48%
Three-Year Dividend Growth-10.94%13.60%42.31%84.37%35.85%
Payout Ratio70.27%36.17%42.88%49.24%49.32%
Years of Consecutive Dividend Growth1 Years1 Years1 Years49 Years49 Years
Debt
Debt-to-Equity Ratio0.51%0.46%2.28%5.40%0.52%
Current Ratio1.48%0.80%1.42%0.83%1.75%
Quick Ratio1.16%0.56%1.10%0.73%1.32%
Ownership Information
Institutional Ownership Percentage64.10%9.50%81.57%65.98%72.99%
Insider Ownership Percentage0.05%0.01%0.13%0.09%1.50%
Miscellaneous
Employees78,500103,91435,00047,000109,000
Shares Outstanding5.60 billion2.29 billion959.03 million1.77 billion1.78 billion
Next Earnings Date10/26/2021 (Estimated)10/26/2021 (Estimated)10/26/2021 (Estimated)10/29/2021 (Estimated)10/20/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Abbott Laboratories (NYSE:ABT) Short Interest UpdateAbbott Laboratories (NYSE:ABT) Short Interest Update
americanbankingnews.com - August 3 at 7:10 PM
Absher Wealth Management, Llc Buys Abbott Laboratories, Annovis Bio Inc, Sony Group Corp, Sells ...Absher Wealth Management, Llc Buys Abbott Laboratories, Annovis Bio Inc, Sony Group Corp, Sells ...
gurufocus.com - August 3 at 1:45 PM
U.S. says Abbott units to pay $160 million to resolve alleged false Medicare claimsU.S. says Abbott units to pay $160 million to resolve alleged false Medicare claims
pharmalive.com - August 3 at 12:46 PM
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the HeartAbbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
finance.yahoo.com - August 3 at 12:46 PM
What Are Abbott Laboratories’s Short-Term Prospects?What Are Abbott Laboratories’s Short-Term Prospects?
stocksregister.com - August 2 at 7:54 PM
New Potomac Partners, LLC Buys Abbott Laboratories, iShares MSCI All Country Asia ex Japan ...New Potomac Partners, LLC Buys Abbott Laboratories, iShares MSCI All Country Asia ex Japan ...
gurufocus.com - August 2 at 2:57 PM
U.S. says Abbott units to pay $160 mln to resolve alleged false Medicare claimsU.S. says Abbott units to pay $160 mln to resolve alleged false Medicare claims
msn.com - August 2 at 2:54 PM
Barclays slashes price target on Abbott Laboratories [ABT] – find out why.Barclays slashes price target on Abbott Laboratories [ABT] – find out why.
dbtnews.com - August 2 at 2:54 PM
Hgk Asset Management Inc Buys Coca-Cola Co, Abbott Laboratories, Alliant Energy Corp, Sells ...Hgk Asset Management Inc Buys Coca-Cola Co, Abbott Laboratories, Alliant Energy Corp, Sells ...
gurufocus.com - July 30 at 8:20 PM
Global Wearable Medical Devices Market Report 2021-2026 Featuring Major Players - Apple, Abbott Laboratories, Dexcom, Fitbit, LG ElectronicsGlobal Wearable Medical Devices Market Report 2021-2026 Featuring Major Players - Apple, Abbott Laboratories, Dexcom, Fitbit, LG Electronics
prnewswire.com - July 30 at 1:31 PM
Abbott Launches Latest Insertable Cardiac Monitor For Irregular Heart RhythmsAbbott Launches Latest Insertable Cardiac Monitor For Irregular Heart Rhythms
feeds.benzinga.com - July 30 at 1:31 PM
Abbott Laboratories (NYSE:ABT) Is Looking To Continue Growing Its Returns On CapitalAbbott Laboratories (NYSE:ABT) Is Looking To Continue Growing Its Returns On Capital
finance.yahoo.com - July 30 at 8:43 AM
Moser Wealth Advisors, LLC Buys Abbott Laboratories, Goldman Sachs Group Inc, Alibaba Group ...Moser Wealth Advisors, LLC Buys Abbott Laboratories, Goldman Sachs Group Inc, Alibaba Group ...
gurufocus.com - July 29 at 9:08 PM
Reviewing Teva Pharmaceutical Industries (NYSE:TEVA) and Abbott Laboratories (NYSE:ABT)Reviewing Teva Pharmaceutical Industries (NYSE:TEVA) and Abbott Laboratories (NYSE:ABT)
americanbankingnews.com - July 29 at 11:21 AM
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical LimitationsNew Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
finance.yahoo.com - July 29 at 9:26 AM
Abbott Laboratories (NYSE:ABT) Releases FY 2021 Earnings GuidanceAbbott Laboratories (NYSE:ABT) Releases FY 2021 Earnings Guidance
americanbankingnews.com - July 29 at 7:41 AM
Analyzing Abbott Laboratoriess Unusual Options ActivityAnalyzing Abbott Laboratories's Unusual Options Activity
benzinga.com - July 28 at 2:10 PM
What Did We Find About Insider Trading At Abbott Laboratories (NYSE: ABT)?What Did We Find About Insider Trading At Abbott Laboratories (NYSE: ABT)?
stocksregister.com - July 28 at 2:10 PM
The Bullish Case for Abbott LaboratoriesThe Bullish Case for Abbott Laboratories
stocknews.com - July 28 at 2:10 PM
Abbott Laboratories [ABT] Is Currently -1.06 below its 200 Period Moving Avg: What Dose This Mean?Abbott Laboratories [ABT] Is Currently -1.06 below its 200 Period Moving Avg: What Dose This Mean?
dbtnews.com - July 27 at 7:05 PM
Abbott Laboratories (ABT) Investors To Make Money AgainAbbott Laboratories (ABT) Investors To Make Money Again
marketingsentinel.com - July 26 at 2:43 PM
William Blair Comments on Abbott Laboratories Q3 2021 Earnings (NYSE:ABT)William Blair Comments on Abbott Laboratories' Q3 2021 Earnings (NYSE:ABT)
americanbankingnews.com - July 26 at 2:34 AM
SVB Leerink Analysts Reduce Earnings Estimates for Abbott Laboratories (NYSE:ABT)SVB Leerink Analysts Reduce Earnings Estimates for Abbott Laboratories (NYSE:ABT)
americanbankingnews.com - July 26 at 2:34 AM
Abbott Laboratories Is Likely To Melt Up Into 2022Abbott Laboratories Is Likely To Melt Up Into 2022
seekingalpha.com - July 25 at 2:21 PM
Custom Pre-earnings Bullish Diagonal Trigger in Abbott LaboratoriesCustom Pre-earnings Bullish Diagonal Trigger in Abbott Laboratories
cmlviz.com - July 25 at 8:08 AM
Abbott Laboratories (NYSE:ABT) Given New $136.00 Price Target at Morgan StanleyAbbott Laboratories (NYSE:ABT) Given New $136.00 Price Target at Morgan Stanley
marketbeat.com - July 23 at 10:07 AM
Abbott Laboratories Proves Its Worth Again Abbott Laboratories Proves Its Worth Again 
marketbeat.com - July 22 at 9:19 AM
The Top 3 Healthcare Stocks to Buy in July (ABT)The Top 3 Healthcare Stocks to Buy in July (ABT)
marketbeat.com - July 6 at 7:23 PM
DateCompanyBrokerageAction
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Reiterated Rating
8/2/2021AbbVieSVB Leerink
Boost Price Target
8/2/2021AbbVieMizuho
Boost Price Target
8/2/2021AbbVieBarclays
Boost Price Target
7/30/2021PfizerMizuho
Boost Price Target
7/29/2021PfizerThe Goldman Sachs Group
Set Price Target
7/29/2021PfizerMorgan Stanley
Boost Price Target
7/29/2021PfizerRoyal Bank of Canada
Set Price Target
7/29/2021PfizerSVB Leerink
Boost Price Target
7/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
7/27/2021PfizerTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/22/2021NovartisDeutsche Bank Aktiengesellschaft
Downgrade
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/17/2021PfizerRoyal Bank of Canada
Boost Price Target
6/15/2021PfizerBerenberg Bank
Reiterated Rating
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021PfizerJPMorgan Chase & Co.
Set Price Target
5/24/2021PfizerThe Goldman Sachs Group
Set Price Target
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/13/2021PfizerThe Goldman Sachs Group
Reiterated Rating
5/12/2021PfizerMizuho
Reiterated Rating
5/11/2021NovartisMorgan Stanley
Reiterated Rating
5/10/2021PfizerMorgan Stanley
Boost Price Target
5/6/2021PfizerMizuho
Downgrade
5/5/2021PfizerSVB Leerink
Boost Price Target
5/5/2021PfizerJPMorgan Chase & Co.
Boost Price Target
5/5/2021PfizerBarclays
Boost Price Target
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/28/2021NovartisJPMorgan Chase & Co.
Reiterated Rating
4/28/2021NovartisOddo Bhf
Upgrade
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/19/2021NovartisUBS Group
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/7/2021PfizerRoyal Bank of Canada
Initiated Coverage
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
4/6/2021PfizerThe Goldman Sachs Group
Set Price Target
3/31/2021PfizerThe Goldman Sachs Group
Set Price Target
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/26/2021PfizerSVB Leerink
Lower Price Target
3/23/2021PfizerBerenberg Bank
Reiterated Rating
3/23/2021NovartisSociete Generale
Reiterated Rating
3/22/2021NovartisSanford C. Bernstein
Initiated Coverage
3/16/2021NovartisArgus
Reiterated Rating
3/15/2021PfizerThe Goldman Sachs Group
Set Price Target
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/11/2021Abbott LaboratoriesRaymond James
Boost Price Target
3/10/2021NovartisArgus
Downgrade
3/9/2021PfizerThe Goldman Sachs Group
Reiterated Rating
2/12/2021Eli Lilly andCowen
Boost Price Target
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
2/3/2021PfizerJPMorgan Chase & Co.
Set Price Target
2/2/2021NovartisMorgan Stanley
Reiterated Rating
2/1/2021NovartisCowen
Downgrade
2/1/2021Eli Lilly andTruist
Boost Price Target
2/1/2021Eli Lilly andMizuho
Boost Price Target
2/1/2021Eli Lilly andBarclays
Boost Price Target
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/28/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
1/28/2021Abbott LaboratoriesCowen
Boost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
1/28/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
1/28/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
1/28/2021Abbott LaboratoriesRaymond James
Boost Price Target
1/28/2021Abbott LaboratoriesBTIG Research
Upgrade
1/22/2021NovartisBarclays
Reiterated Rating
1/22/2021Eli Lilly andBank of America
Boost Price Target
1/19/2021Eli Lilly andMizuho
Upgrade
1/15/2021NovartisDeutsche Bank Aktiengesellschaft
Initiated Coverage
1/8/2021NovartisMorgan Stanley
Reiterated Rating
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
12/15/2020Abbott LaboratoriesMorgan Stanley
Boost Price Target
12/3/2020NovartisArgus
Boost Price Target
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/25/2020NovartisUBS Group
Reiterated Rating
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/10/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
11/2/2020AbbVieSVB Leerink
Lower Price Target
10/23/2020AbbVieTruist
Initiated Coverage
10/20/2020AbbVieThe Goldman Sachs Group
Downgrade
10/16/2020AbbVieJPMorgan Chase & Co.
Boost Price Target
9/29/2020NovartisBerenberg Bank
Initiated Coverage
9/29/2020AbbVieBerenberg Bank
Initiated Coverage
9/23/2020NovartisOddo Bhf
Downgrade
9/10/2020NovartisUBS Group
Upgrade
9/1/2020NovartisMorgan Stanley
Upgrade
8/12/2020NovartisJPMorgan Chase & Co.
Reiterated Rating
7/28/2020NovartisMorgan Stanley
Reiterated Rating
6/15/2020NovartisCitigroup
Upgrade
(Data available from 8/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.